525 related articles for article (PubMed ID: 25336925)
1. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma.
Zhao YY; Tian Y; Liu L; Zhan JH; Hou X; Chen X; Zhou T; Huang Y; Zhang L
Drug Des Devel Ther; 2018; 12():2655-2663. PubMed ID: 30214154
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.
Ma BB; Lui VW; Hui CW; Lau CP; Wong CH; Hui EP; Ng MH; Tsao SW; Li Y; Chan AT
Invest New Drugs; 2013 Jun; 31(3):567-75. PubMed ID: 23143779
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway.
Guo S; Zhang J; Wei C; Lu Z; Cai R; Pan D; Zhang H; Liang B; Zhang Z
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1097-1108. PubMed ID: 32449143
[TBL] [Abstract][Full Text] [Related]
6. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
7. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Simioni C; Neri LM; Tabellini G; Ricci F; Bressanin D; Chiarini F; Evangelisti C; Cani A; Tazzari PL; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Capitani S; Martelli AM
Leukemia; 2012 Nov; 26(11):2336-42. PubMed ID: 22614243
[TBL] [Abstract][Full Text] [Related]
10. Picropodophyllin inhibits tumor growth of human nasopharyngeal carcinoma in a mouse model.
Yin SC; Guo W; Tao ZZ
Biochem Biophys Res Commun; 2013 Sep; 439(1):1-5. PubMed ID: 23973483
[TBL] [Abstract][Full Text] [Related]
11. 14-Thienyl methylene matrine (YYJ18), the derivative from matrine, induces apoptosis of human nasopharyngeal carcinoma cells by targeting MAPK and PI3K/Akt pathways in vitro.
Xie M; Yi X; Wang R; Wang L; He G; Zhu M; Qi C; Liu Y; Ye Y; Tan S; Tang A
Cell Physiol Biochem; 2014; 33(5):1475-83. PubMed ID: 24854624
[TBL] [Abstract][Full Text] [Related]
12. [Circadian rhythms of DNA synthesis and apoptosis correlated gene expression in bone marrow cells of nude mice bearing human nasopharyngeal carcinoma].
Sun J; Xian LJ; Cao QY; Ye YL; Zeng ZL; Liu XH; Li XM; Levi F
Ai Zheng; 2002 Aug; 21(8):833-7. PubMed ID: 12478887
[TBL] [Abstract][Full Text] [Related]
13. Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes.
Tan S; Ng Y; James DE
Biochem J; 2011 Apr; 435(2):539-44. PubMed ID: 21348862
[TBL] [Abstract][Full Text] [Related]
14. OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma Progression in vitro and in vivo.
Ding L; Ren C; Yang L; Wu Z; Li F; Jiang D; Zhu Y; Lu J
Drug Des Devel Ther; 2021; 15():1797-1810. PubMed ID: 33958857
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
Wong CH; Loong HH; Hui CW; Lau CP; Hui EP; Ma BB; Chan AT
Invest New Drugs; 2013 Dec; 31(6):1399-408. PubMed ID: 23975511
[TBL] [Abstract][Full Text] [Related]
16. C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines.
Huang PY; Hong MH; Zhang X; Mai HQ; Luo DH; Zhang L
Chin J Cancer; 2010 Feb; 29(2):131-5. PubMed ID: 20109338
[TBL] [Abstract][Full Text] [Related]
17. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
18. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
19. Salinomycin inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cell in vitro and suppresses tumor growth in vivo.
Wu D; Zhang Y; Huang J; Fan Z; Shi F; Wang S
Biochem Biophys Res Commun; 2014 Jan; 443(2):712-7. PubMed ID: 24333874
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol enhances the radiosensitivity of nasopharyngeal carcinoma cells by downregulating E2F1.
Tan Y; Wei X; Zhang W; Wang X; Wang K; Du B; Xiao J
Oncol Rep; 2017 Mar; 37(3):1833-1841. PubMed ID: 28184930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
